Optimizing the treatment of haemophilia B: laboratory and clinical perspectives.
Hemophilia A and B are traditionally thought of as a single bleeding disorder, viewed as opposite sides of the same coin. Yet the differences between the 2 forms of congenital hemophilia extend far beyond the type of deficient clotting factor--factor VIII for hemophilia A and factor IX (FIX) for hemophilia B. This supplement focuses on the unique laboratory and clinical issues associated with FIX replacement therapy for children and adults with hemophilia B.
Aledort
L M
LM
Mount Sinai School of Medicine, New York, NY 10029, USA. louis.aledort@mountsinai.org
D000328:Adult; D002648:Child; D005164:Factor IX / Q000627:therapeutic use*; D002836:Hemophilia B / Q000188:drug therapy*; D006470:Hemorrhage / Q000517:prevention & control; D006801:Humans; D011994:Recombinant Proteins / Q000627:therapeutic use
D011994:Recombinant Proteins; D005164:Factor IX